Amlodipine/azilsartan

Drug Profile

Amlodipine/azilsartan

Alternative Names: Amlodipine besylate/azilsartan FDC - Takeda; Azilsartan/amlodipine; Azilsartan/amlodipine besylate; TAK-536/amlodipine; TAK-536CCB; Zacras

Latest Information Update: 19 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Dihydropyridines; Oxadiazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 18 Jun 2014 Launched for Hypertension in Japan (PO) - First global launch
  • 24 Mar 2014 Registered for Hypertension in Japan (PO) - First global approval
  • 26 Apr 2013 Safety and efficacy data from a phase III trial in Hypertension released by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top